权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A microfluidic platform to study sickle blood rheology

研究镰状血液流变学的微流控平台

基本信息

批准号：
9684422
负责人：
David Kevin Wood
金额：
$ 6.67万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-01 至 2021-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9684422
关键词：
Address Adult Affect Affinity Binding Biological Markers Blood Blood Pressure Blood Vessel Tissue Blood Viscosity Blood flow Blood specimen Caring Cells Cessation of life Clinical Dependence Development Devices Dimensions Disease Erythrocytes Fiber Genetic Diseases Geometry Health Care Costs Hemoglobin Hereditary Disease Human In Vitro Individual Infarction Investigational Therapies Measures Microfluidics Morbidity - disease rate Organ Oxygen Patient Monitoring Patients Pharmaceutical Preparations Phase Physiological Polymers Probability Process Quality of life Research Risk Role Severity of illness Sickle Cell Sickle Cell Anemia Sickle Hemoglobin Suspensions System Testing Tissues Variant Viscosity Work blood rheology blood vessel occlusion falls improved in vivo mortality mutant novel novel therapeutics patient biomarkers patient stratification polymerization pressure response sickling

项目摘要

Sickle cell disease (SCD) is a devastating hereditary disorder that affects more than 13 million people worldwide with health care costs in the U.S. alone exceeding $1 billion per year. The origin of SCD is a mutant hemoglobin molecule (sickle hemoglobin or HbS) that polymerizes into rigid fibers when deoxygenated. These fibers cause large changes in blood rheology and can ultimately result in complete occlusion of blood vessels, tissue infarction, organ damage, and even death. Despite more than 100 years of research, a clear picture of the vaso-occlusive process remains elusive, and the result is a dearth of treatment options and poor quality of life for the millions of individuals who suffer from this disease. Low oxygen concentration is the one necessary condition for morbidity and mortality in sickle disease, but the quantitative relationship between oxygen concentration and sickle cell blood rheology in physiologic regimes of pressure, vessel size, and hemoglobin concentration is unknown. Ultimately, clinical progress in sickle cell disease requires that we understand how low can a patient's tissue oxygen level fall before a vaso-occlusion will occur, how changes in pressure and vessel dilation modulate the probability of vaso-occlusion at different oxygen concentrations, and how sensitive vaso-occlusion is to slight changes in hemoglobin concentration. Thus, our Specific Aims in these studies are to: (1) Determine the quantitative relationship between sickle blood rheology and blood oxygen concentration; (2) Quantify the effect of vessel size and blood pressure on the relationship between sickle blood rheology and oxygen concentration; (3) Quantify the effect of sickle hemoglobin concentration on the relationship between sickle blood rheology and oxygen concentration. Our primary hypothesis is that the relationship between blood viscosity and oxygen concentration comprises multiple functional regimes, characterized by critical oxygen thresholds, and that this relationship is sensitive to vessel size, blood pressure, and HbS concentration in vivo. Because these parameters cannot be controlled in vivo, we will use an in vitro microfluidic platform with oxygen control to systematically vary these parameters and quantify the effects on sickle blood rheology. The phase space of sickle blood rheology, such as the oxygen thresholds, may be modulated by treatments such as drugs that modulate hemoglobin oxygen binding affinity. Thus, the platforms developed here would be ideal for testing such therapies. The parameters uncovered in these studies may also serve as biomarkers for disease severity to indicate which patients are most in need of care or when patients are most at risk of complications. Overall, the results of these studies will be a clearer understanding of how sickle blood rheology depends on critical physiologic parameters, and this work will produce new platforms and biomarkers for patient monitoring and for prioritizing experimental therapies.

镰状细胞病（SCD）是一种毁灭性的遗传性疾病，影响着1300多万人